Acinetobacter baumannii (A. baumannii), an opportunistic, gram-negative pathogen, has evoked the interest of the medical community throughout the world because of its ability to cause nosocomial infections, majorly infecting those in intensive care units. It has also drawn the attention of researchers due to its evolving immune evasion strategies and increased drug resistance. The emergence of multi-drug-resistant-strains has urged the need to explore novel therapeutic options as an alternative to antibiotics. Due to the upsurge in antibiotic resistance mechanisms exhibited by A. baumannii, the current therapeutic strategies are rendered less effective. The aim of this study is to explore novel therapeutic alternatives against A. baumannii to control the ailed infection. In this study, a computational framework is employed involving, pan genomics, subtractive proteomics and reverse vaccinology strategies to identify core promiscuous vaccine candidates. Two chimeric vaccine constructs having B-cell derived T-cell epitopes from prioritized vaccine candidates; APN, AdeK and AdeI have been designed and checked for their possible interactions with host BCR, TLRs and HLA Class I and II Superfamily alleles. These vaccine candidates can be experimentally validated and thus contribute to vaccine development against A. baumannii infections.

鲍曼不动杆菌 (A. baumannii)是一种机会性革兰氏阴性病原体，由于其能够引起院内感染，尤其是重症监护病房中的感染者，引起了全世界医学界的兴趣。由于其不断发展的免疫逃避策略和增加的耐药性，它也引起了研究人员的注意。多重耐药菌株的出现促使人们需要探索新的治疗方案来替代抗生素。由于鲍曼不动杆菌表现出的抗生素耐药机制激增，目前的治疗策略变得不太有效。本研究的目的是探索针对鲍曼不动杆菌的新型治疗方案以控制生病的感染。在这项研究中，采用了一个计算框架，涉及泛基因组学、减法蛋白质组学和反向疫苗学策略，以确定核心混杂疫苗候选者。两种嵌合疫苗构建体具有来自优先候选疫苗的 B 细胞衍生 T 细胞表位；APN 、 AdeK 和 AdeI 已被设计并检查它们与宿主 BCR、TLR 和 HLA I 类和 II 类超家族等位基因的可能相互作用。这些候选疫苗可以通过实验验证，从而有助于针对鲍曼不动杆菌感染的疫苗开发。